Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. NVDA
9. CRWV
10. CME

Go back to Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
(NASDAQ: APVO) Delayed: 6.40 -0.06 (0.93%)
Previous Close $6.46    52 Week High $4.33 
Open $6.49    52 Week Low $1.80 
Day High $6.51    P/E N/A 
Day Low $6.35    EPS $0.00 
Volume 5,479